Literature DB >> 16216172

The role of ubiquitous airborne fungi in chronic rhinosinusitis.

Jens U Ponikau1, David A Sherris, Gail M Kephart, Cheryl Adolphson, Hirohito Kita.   

Abstract

Chronic rhinosinusitis (CRS) is a confusing disease for both allergists and otorhinolaryngologists, partially due to its poorly understood pathophysiology and partially due to its limited treatment options. Several recent reports now provide evidence for a better understanding of the etiology and the relationship of CRS to airborne fungi, especially to Alternaria. First, the development of novel methods enables detection of certain fungi in mucus from the nasal and paranasal sinus cavities. Second, a non-immunoglobulin E-mediated immunologic mechanism for reactivity of CRS patients to certain common fungi has been described. Third, these fungi are surrounded by eosinophils in vivo, suggesting that they are targeted by eosinophils. Fourth, the preliminary results of studies using antifungal agents to treat patients with CRS are promising. Overall, these recent discoveries provide a logical mechanism for the pathophysiology of CRS, and they also suggest promising avenues for treatment of CRS with antifungal agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216172     DOI: 10.1007/s11882-005-0028-6

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  38 in total

1.  Summary health statistics for U.S. adults: National Health Interview Survey, 2002.

Authors:  Margaret Lethbridge-Cejku; Jeannine S Schiller; Luther Bernadel
Journal:  Vital Health Stat 10       Date:  2004-07

2.  Validity of a new health-related quality of life instrument for patients with chronic sinusitis.

Authors:  Steven J Atlas; Ralph B Metson; Daniel E Singer; Yen A Wu; Richard E Gliklich
Journal:  Laryngoscope       Date:  2005-05       Impact factor: 3.325

3.  Chronic rhinosinusitis: is the nose really involved?

Authors:  N Bhattacharyya
Journal:  Am J Rhinol       Date:  2001 May-Jun

4.  Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial.

Authors:  Jens U Ponikau; David A Sherris; Amy Weaver; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2005-01       Impact factor: 10.793

5.  Detection of fungal organisms in eosinophilic mucin using a fluorescein-labeled chitin-specific binding protein.

Authors:  Matthew J Taylor; Jens U Ponikau; David A Sherris; Eugene B Kern; Thomas A Gaffey; Gail Kephart; Hirohito Kita
Journal:  Otolaryngol Head Neck Surg       Date:  2002-11       Impact factor: 3.497

6.  Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial.

Authors:  Michael Weschta; Dagmar Rimek; Marc Formanek; Doreen Polzehl; Andreas Podbielski; Herbert Riechelmann
Journal:  J Allergy Clin Immunol       Date:  2004-06       Impact factor: 10.793

7.  Skin testing in predicting response to nasal provocation with alternaria.

Authors:  John H Krouse; Anand G Shah; Kristy Kerswill
Journal:  Laryngoscope       Date:  2004-08       Impact factor: 3.325

8.  GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP).

Authors:  D L Hamilos; D Y Leung; D P Huston; A Kamil; R Wood; Q Hamid
Journal:  Clin Exp Allergy       Date:  1998-09       Impact factor: 5.018

9.  Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma?

Authors:  Jens U Ponikau; David A Sherris; Gail M Kephart; Eugene B Kern; Thomas A Gaffey; James E Tarara; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2003-11       Impact factor: 10.793

10.  Cytotoxicity of human eosinophil granule major basic protein to human nasal sinus mucosa in vitro.

Authors:  K Hisamatsu; T Ganbo; T Nakazawa; Y Murakami; G J Gleich; K Makiyama; H Koyama
Journal:  J Allergy Clin Immunol       Date:  1990-07       Impact factor: 10.793

View more
  8 in total

1.  Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33.

Authors:  Douglas D Reh; Yadong Wang; Murugappan Ramanathan; Andrew P Lane
Journal:  Am J Rhinol Allergy       Date:  2010 Mar-Apr       Impact factor: 2.467

2.  Endoscopic endonasal sinus surgery: a review of 18 years of practice and long-term follow-up.

Authors:  Arild Danielsen; Jan Olofsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-08-26       Impact factor: 2.503

3.  The role of hepatocyte growth factor/c-Met in chronic rhinosinusitis with nasal polyps.

Authors:  Douglas D Reh; Murugappan Ramanathan; Babar Sultan; Yadong Wang; Lindsey May; Andrew P Lane
Journal:  Am J Rhinol Allergy       Date:  2010 Jul-Aug       Impact factor: 2.467

Review 4.  Global airway disease beyond allergy.

Authors:  Peter W Hellings; Emmanuel P Prokopakis
Journal:  Curr Allergy Asthma Rep       Date:  2010-03       Impact factor: 4.806

5.  Failure of itraconazole to prevent T-helper type 2 cell immune deviation: Implications for chronic rhinosinusitis.

Authors:  Joshua L Kennedy; John W Steinke; Lixia Liu; Julie Negri; Larry Borish; Spencer C Payne
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

Review 6.  Fungal disease of the nose and sinuses: an updated overview.

Authors:  Christopher Chang; M Eric Gershwin; George R Thompson
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

Review 7.  Actual concepts in rhinosinusitis: a review of clinical presentations, inflammatory pathways, cytokine profiles, remodeling, and management.

Authors:  Philippe Eloy; Anne Lise Poirrier; Clotilde De Dorlodot; Thibaut Van Zele; Jean Baptiste Watelet; Bernard Bertrand
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

8.  In vivo determination of mouse olfactory mucus cation concentrations in normal and inflammatory states.

Authors:  Senthil Selvaraj; Kevin Liu; Alan M Robinson; Victoria A Epstein; David B Conley; Robert C Kern; Claus-Peter Richter
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.